Trial Profile
A Prospective Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Tinzaparin sodium
- Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Therapeutic Use
- 24 Oct 2017 Status changed from not yet recruiting to recruiting.
- 08 Aug 2017 New trial record